Boston University’s Dr. Helen Tager-Flusberg to Join Q BioMed’s Advisory Committee

Q BioMed Inc., a biotechnology acceleration company, announced today that Dr. Helen Tager-Flusberg from Boston University has joined its advisory committee for QBM-001, which is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Dr. Tager-Flusberg has provided the protocol for capturing the primary endpoint of the planned trial for […]